Coronado Biosciences

Coronado Biosciences is engaged in the development of novel immunotherapy biologic agents. The Company’s two principal pharmaceutical product candidates in clinical development are: CNDO-201, a biologic for the treatment of autoimmune diseases, such as Crohn’s disease, ulcerative colitis and multiple sclerosis; and CNDO-109, a biologic that activates natural killer cells, for the treatment of acute myeloid leukemia and solid tumors.

The Company recently completed a $25.8 million round of financing and is using the proceeds to advance its pipeline, including funding Phase II double-blind, placebo controlled trial of CNDO-201 for the treatment of Crohn’s Disease scheduled for initiation in early 2012 and a Phase I/II dose escalation and expansion trial of CNDO-109 for the treatment of relapsed Acute Myeloid Leukemia (AML) planned for 2012. Each of these drugs is a novel therapy that has achieved clinical proof-of-concept in indications with unmet medical needs.

AT A GLANCE | COMPANY NEWS | COMPANY WEBSITE |SEC FILINGS | STOCK QUOTE


Comments are closed.